Latest news with #JamesSteel
Edinburgh Reporter
7 days ago
- Sport
- Edinburgh Reporter
Celebration week planned for Dean bowlers
Founded in 1900 by Sir James Steel, Edinburgh Lord Provost and a noted builder and businessman, Dean Bowling Club are currently marking their 125th anniversary. A week of celebrations are planned on the Comely Bank green from Saturday 14-21 June. All welcome. In the year 2000, when celebrating their milestone, Edinburgh City Council awarded the club a Civic Reception which was hosted by Lord Provost Eric Milligan. At that time there was a membership of about 150 and while, like many clubs, numbers started to reduce with hard work and perseverance Dean are on the way back up and currently sit at just over 100 members. The club are always looking for new members and a drive began on the annual Opening Day in April which was attended by Depute Lord Provost Lezley Marion Cameron and Councillors Vicky Nicolson and Max Mitchell. Full Membership for a new member's first year is fixed at £50, doubling in the second year. Thereafter the value is decided at the club AGM. Social Membership is £40 annually. The club has a strong coaching element within its membership and this mostly takes place on a Friday evening from 5.30-7pm. For more info go to: Like this: Like Related
Yahoo
26-03-2025
- Business
- Yahoo
Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting
LONDON and PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will have three presentations at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025 in Chicago, IL. The poster presentations will feature data from the Company's proprietary pre|CISION® platform and pipeline of next generation peptide drug conjugates (PDCs), including AVA6000, a PDC consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by FAP in the tumor microenvironment via a pharmacokinetics and clinical presentation, and preclinical pharmacology highlights for AVA6103, a PDC comprised of the pre|CISION® peptide linked to exatecan. The third presentation will describe detailed analysis of the target fibroblast activation protein-alpha (FAPα), the protease that forms the basis of the pre|CISION® platform. Details for Avacta's poster presentations are below and can be found on the AACR website: Abstract Number and Title: #3139: The novel PDC AVA6103 is a FAP-enabled pre|CISION® medicine which targets exatecan, a topoisomerase I inhibitor, to the tumor microenvironment following FAP cleavage Session Category: Experimental and Molecular Therapeutics Session Title: Therapeutic Approach to Attack the Tumor Microenvironment Session Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CT Abstract Number and Title: #2699: Investigating fibroblast activation protein alpha (FAPα) as a therapeutic target for delivery of pre|CISION® cancer medicines: Expression, spatial localization and functional insights Session Category: Tumor Biology Session Title: Targeting the Tumor Microenvironment: A Brave New World Session Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CT Abstract Number and Title: #CT15: Comparative pharmacokinetics and tumor activation of fibroblast activation protein (FAP)-enabled pre|CISION® peptide drug conjugates Session Title: First-in-Human Phase I Clinical Trials 2 Session Date and Time: Tuesday, April 29, 2025, 9:00 a.m. - 12:00 p.m. CT For further information from Avacta, please contact: Avacta Group plcMichael Vinegrad, Group CommunicationsDirector Peel Hunt (Nomad and Broker)James Steel / Chris Golden Panmure Liberum (Joint Broker)Emma Earl / Will Goode / Mark Rogers ICR HealthcareMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert avacta@ Investor ContactRenee Leck THRUST Strategic Communications renee@ Media ContactCarly ScadutoCarly Scaduto Consulting Carly@ About Avacta - Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates. About the pre|CISION® PlatformThe pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for in to access your portfolio
Yahoo
10-03-2025
- Business
- Yahoo
Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference
LONDON and PHILADELPHIA , March 10, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will present at the Leerink Global Healthcare Conference on Wednesday, March 12, 2025, at 10:00 a.m. ET in Miami. A live webcast of the presentation will be available in the investors section of the Company's website at The webcast will be archived for at least 30 days following the presentation. For further information from Avacta, please contact: Avacta Group plcMichael Vinegrad, Group CommunicationsDirector Peel Hunt (Nomad and Broker)James Steel / Chris Golden / Patrick Birkholm Panmure Liberum (Joint Broker)Emma Earl / Will Goode / Mark Rogers ICR HealthcareMary-Jane Elliott / Jessica Hodgson / Max Bennett avacta@ Investor ContactRenee Leck THRUST Strategic Communications renee@ Media ContactCarly ScadutoCarly Scaduto Consulting Carly@ About Avacta - Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates. About the pre|CISION® PlatformThe pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for in to access your portfolio
Yahoo
10-03-2025
- Business
- Yahoo
Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference
LONDON and PHILADELPHIA , March 10, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will present at the Leerink Global Healthcare Conference on Wednesday, March 12, 2025, at 10:00 a.m. ET in Miami. A live webcast of the presentation will be available in the investors section of the Company's website at The webcast will be archived for at least 30 days following the presentation. For further information from Avacta, please contact: Avacta Group plcMichael Vinegrad, Group CommunicationsDirector Peel Hunt (Nomad and Broker)James Steel / Chris Golden / Patrick Birkholm Panmure Liberum (Joint Broker)Emma Earl / Will Goode / Mark Rogers ICR HealthcareMary-Jane Elliott / Jessica Hodgson / Max Bennett avacta@ Investor ContactRenee Leck THRUST Strategic Communications renee@ Media ContactCarly ScadutoCarly Scaduto Consulting Carly@ About Avacta - Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates. About the pre|CISION® PlatformThe pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for in to access your portfolio
